Cavitation Technologies board recommends shareholders accept BrightFlixx offer
CVAT•CVAT•CVAT•CVAT•Cavitation Technologies’ board unanimously recommended that shareholders accept BrightFlixx Finance’s cash offer for all outstanding shares, with estimated consideration of $0.0975–$0.1029 per share. The offer expires January 26, 2027, subject to extensions for review of final pricing.
Cavitation Technologies’ board unanimously backed BrightFlixx Finance’s cash offer for all outstanding shares as its initial recommendation. Estimated consideration is $0.0975–$0.1029 per share, calculated as $35 million less liabilities divided by shares outstanding on December 24, 2026.
BrightFlixx also seeks all shares of Alchemy Beverages, a 13.3%-owned affiliate. Alchemy’s board remains neutral pending an independent fairness opinion, and both companies may seek higher prices if the opinion values Alchemy above $7 million; final recommendations await its review.
The offers expire January 26, 2027, at 11:59 p.m. Pacific. Extensions will ensure shareholders have at least 30 business days to review final pricing.
